Galectin Therapeutics
GALT
49 hedge funds and large institutions have $8.3M invested in Galectin Therapeutics in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 8 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
0.38% less ownership
Funds ownership: 11.48% → 11.1% (-0.38%)
6% less funds holding
Funds holding: 52 → 49 (-3)
15% less capital invested
Capital invested by funds: $9.77M → $8.3M (-$1.47M)
21% less call options, than puts
Call options by funds: $523K | Put options by funds: $659K
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$165K |
| 2 |
AG
Advisor Group
Phoenix,
Arizona
|
+$71K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$56.8K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$45.7K |
| 5 |
MML Investors Services
Springfield,
Massachusetts
|
+$22.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARTA
A.R.T. Advisors
New York
|
-$112K |
| 2 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
-$94.2K |
| 3 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$70K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$40.7K |
| 5 |
Millennium Management
New York
|
-$27K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIM
51
Acrospire Investment Management
Chicago,
Illinois
| – | -$16K | -6,575 | Closed |
|
52
First Manhattan
New York
| – | -$4K | -1,667 | Closed |
|
53
Creative Planning
Overland Park,
Kansas
| – | -$3K | -1,150 | Closed |
|
54
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$198 | -100 | -98% |
|
55
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$46 | +23 | +767% |
|
GALT Hedge Fund Activity: Q3 2017 in Review
49 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q3 2017, worth a combined $8.3M — down 15% from $9.77M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of GALT and 6 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 9 added.
The largest buyer was Susquehanna International Group, adding an estimated $165K. The largest seller was A.R.T. Advisors, exiting entirely with an estimated $112K sold.
- 49 institutional investors held Galectin Therapeutics (GALT) as of Q3 2017, down from 52 in Q2 2017.
- Funds reported $8.3M of Galectin Therapeutics stock for Q3 2017, down 15% quarter-over-quarter.
- 6 funds opened new Galectin Therapeutics positions in Q3 2017 and 8 closed out, a net change of -2 holders.
- The largest Galectin Therapeutics buyer in Q3 2017 was Susquehanna International Group, an estimated $165K added.
- The largest Galectin Therapeutics seller in Q3 2017 was A.R.T. Advisors, an estimated $112K sold.
Based on aggregated 13F filings for Q3 2017.